Developer docs
API playgroundTry for free, no card

Search company profiles

Sensius

Full company profile

uuid0002crx

Namestring
Sensius
Legal namestring
Sensius B.V.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Sensius B.V. is a Dutch medical device company developing precision thermotherapy systems for solid tumor treatment, founded in 2015 as a spin-off from Erasmus MC Cancer Institute in Rotterdam. The company targets oncology departments at major cancer treatment centers, initially focused on head and neck cancer with planned expansion into breast cancer, melanoma, and sarcoma. Sensius's core value proposition is enhancing the efficacy of radiotherapy, chemotherapy, and immunotherapy by heating tumors to 40-44°C while preserving surrounding healthy tissue, addressing the 50% recurrence rate in head and neck cancer patients and reducing treatment toxicity without adding systemic side effects.

Sensius's platform centers on the FocusCore base unit, which houses 20 independently controlled microwave amplifiers, water cooling systems, and integrated control computers. Body-site specific applicators connect to the FocusCore: the FocusCollar for head and neck cancer (initial commercial product), with pipeline products including FocusCup (breast cancer with chemotherapy), FocusBlanket (melanoma with immunotherapy), and FocusExtremity (sarcoma for arms and legs). The FocusControl software, based on patented WaveAdapt technology, provides adaptive treatment planning customized per patient. Two patents protect the HyperCollar4D technology. Sensius holds ISO 13485:2016 certification (obtained February 2024), with regulatory filings planned for CE Mark in Europe, UKCA marking in early 2026, and IDE filing in the USA. Clinical evidence is being built through 70+ prototype treatments at Erasmus MC, with the TRIHAN trial demonstrating 81.8% complete response in recurrent HNC patients and a 50% improvement over radiotherapy alone.

Sensius operates a B2B enterprise sales model targeting hospitals and cancer centers, with revenue intended to come primarily through capital equipment sales of the Focus system plus body-site applicators. The go-to-market relies on clinical trial partnerships at leading academic centers (Erasmus MC, Charité Berlin, UK clinics, US clinics), followed by regulatory approval and reimbursement-driven adoption. Channel partners support international distribution: AMG Medtech covers the UK and Ireland, while Andromedic represents Sensius in Italy. The Netherlands has reimbursement in place, with roadmaps being developed for Germany, the UK, and the USA. Pre-commercial at present, Sensius is funded by €21.7M+ in equity and grants, with a €15M Series A completed in June 2025 led by GrayBella Capital and UCEA Capital Partners.

Short descriptiontext

Sensius B.V. is a Dutch medical device company developing the modular Focus thermotherapy platform (FocusCore base unit with body-site applicators) that heats solid tumors to 40-44°C to enhance radiotherapy, chemotherapy, and immunotherapy efficacy, initially targeting head and neck cancer clinics across Europe, the UK, and the USA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRotterdam, Netherlands
HQ citystring
Rotterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision thermotherapy, oncology medical devices, microwave hyperthermia systems, cancer treatment devices, adaptive treatment planning
Industry2 codes
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAFAC
Radiation Oncology
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Oncology Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (Focus System)
TypeHardware Sales
Description

Sensius generates revenue from selling its thermotherapy medical device system (FocusCore + applicators) to hospitals and cancer treatment centers. The system is modular, with a base unit and body-site specific applicators sold as add-ons. Pricing follows a capital equipment model typical for medical devices, with reimbursement enabling hospital procurement.

sensiusthermotherapy.com
2Clinical Trial Services
TypeProfessional Services
Description

Revenue may be generated through clinical trial support and product development collaborations with research institutions, funded via grants and partnership agreements.

sensiusthermotherapy.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1FocusCollar
Description

Body-site specific add-on to FocusCore for head and neck cancer treatment with positioning antennas and bolus

sensiusthermotherapy.com
+5 more records
Core offering1 text field

Sensius develops a precision thermotherapy medical device system that delivers controlled microwave hyperthermia (40-44°C) to solid tumors in combination with radiotherapy, chemotherapy, or immunotherapy. The modular Focus platform consists of the FocusCore base unit (height-adjustable bed, twenty independently controlled microwave amplifiers, water cooling, control computers) and body-site specific applicators (FocusCollar for head and neck cancer, FocusCup for breast cancer, FocusBlanket for melanoma, FocusExtremity for sarcoma). Treatment is planned and delivered via the FocusControl software based on patented WaveAdapt technology with MR-based temperature measurement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 50% improvement in complete response rate when thermotherapy added to radiotherapy (vs radiotherapy alone in TRIHAN trial)
+5 more records
Product overview1 text field

Sensius offers a modular thermotherapy platform consisting of the FocusCore base unit and body-site specific applicators (FocusCollar, FocusCup, FocusBlanket, FocusExtremity) with associated FocusControl treatment planning software. The FocusCore houses twenty independently controlled microwave amplifiers, water pumps, and control systems that power the various applicators. The FocusCollar is the initial commercial launch product for head and neck cancer, while FocusCup (breast cancer), FocusBlanket (melanoma), and FocusExtremity (sarcoma) are in the pipeline for expansion to other solid tumors. The system delivers targeted heating to tumors at 40-44°C in combination with radiotherapy, chemotherapy, or immunotherapy to enhance treatment efficacy.

Product and service7 records
1FocusCore
CategoryOncology Medical Devices
Description

Base unit comprising a height-adjustable bed, twenty independently controlled microwave amplifiers, water pumps and cooling system, nurse station and control computers. The modular core system that powers all body-site specific applicators and contains all components needed for treatment of all tumor types.

2FocusCollar
CategoryOncology Medical Devices
Description

Body-site specific add-on to FocusCore for head and neck cancer treatment. Positions antennas around the target area and connects microwave energy to the body via a body-site specific bolus, redesigned with novel technology from Erasmus MC and TU-Delft for improved antenna-to-patient connection and focused energy delivery.

3FocusControl
CategoryTreatment Planning Software
Description

Software providing accurate treatment preparation and delivery, customized to individual patients. Based on WaveAdapt patented technology, includes automated steering of heat treatment using MR-based temperature measurement across the entire target volume.

4HyperCollar4D (Focus System)
CategoryOncology Medical Devices
Description

Next-generation thermotherapy device that increases effectiveness of radiotherapy for head and neck cancer by warming tumors to 43°C. The first device to achieve effective and cost-efficient hyperthermia treatments for head and neck cancer, protected by two patents (one granted, one filed).

5FocusCup
CategoryOncology Medical Devices
Description

Breast cancer applicator in development for use with chemotherapy, expanding the Focus product family to additional solid tumor types by enhancing chemotherapy efficacy through targeted thermotherapy.

6FocusBlanket
CategoryOncology Medical Devices
Description

Melanoma treatment applicator in development for use with immunotherapy, expanding thermotherapy applications to skin cancer by activating immune response through controlled heating.

7FocusExtremity
CategoryOncology Medical Devices
Description

Sarcoma treatment applicator for arms and legs in development for use with chemotherapy, extending thermotherapy to extremity tumors.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1US Clinical Trial Network (6 clinics)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-06
Description

6 US-based clinics participated in Phoenix meeting (ASTRO) to discuss Phase I-III clinical protocols for FDA clearance and reimbursement. Led by Jason Molitoris (UoM Baltimore) with Mark Hurwitz (MC Westchester) presenting mechanism of action.

sensiusthermotherapy.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-20
Description

SENS-THERM project partner (electromagnetic sensing, video control, metamodeling in thermotherapy for H&N cancers). Prof. Maarten Paulides leads EM4C&C lab at TU/e. Co-founder Prof. Paulides maintains academic appointment.

3UK Thermotherapy Special Interest Group
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-20
Description

Multi-clinic collaboration including Kings College London, Queen Elizabeth Hospital Birmingham, and Clatterbridge Cancer Centre, with NHS radiotherapy ODN and MacMillan Cancer Support representation. Organized by Prof. Bodis and AMG Medtech.

sensiusthermotherapy.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-03
Description

Letter of Intent signed at ESHO Cologne for marketing and sales in Italy. Andromedic is an established hyperthermia device manufacturer selling capacitive devices in Europe and SE Asia. Will represent Sensius as sales agent and collaborate on Italian oncology society engagement and clinical trial design for reimbursement.

5Prof. Stephan Bodis (Medical Advisor)
Strategic tierCoreTypeOthersAnnounced on2023-09-13
Description

Prof. Em. Stephan Bodis serves as senior medical advisor. Previously head of department at Kantonspital Aarau, where he established hyperthermia reimbursement in Switzerland and built Swiss Hyperthermia Network of 15 clinics. Brings 20 years of hyperthermia leadership.

sensiusthermotherapy.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-29
Description

Letter of Intent for cooperation on thermotherapy introduction for head and neck cancer. University hospital and tertiary specialized center for H&N cancer in Switzerland. Dr. Emanuel Stutz involved.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-29
Description

Letter of Intent for cooperation on thermotherapy for head and neck cancer. Driver of Swiss Hyperthermia Network (15 clinics). Prof. Dr. med. Oliver Riesterer chairs radiotherapy. Prof. Stephan Bodis previously built hyperthermia department here.

8AMG Medtech Limited
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-02
Description

UK and Ireland commercial partnership. AMG represents Sensius in these territories and aims to build a network of clinics for clinical trials followed by nationwide adoption. Medical imaging consultancy with extensive radiotherapy community network.

sensiusthermotherapy.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-26
Description

LOI signed for cooperation in product development, consultancy, reimbursement, and clinical trials. Prof. Dr. Daniel Zips (Head of department) leads. Will conduct first-in-patient testing for CE marking, followed by clinical trials and German reimbursement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-24
Description

Partnership for development and production of Sensius thermotherapy device, transitioning prototype to commercial medical device. Technobis specializes in medical device development.

11Motive Engineering
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-24
Description

Partnership for medical device software development as part of consortium with Technobis and Sensius. Extensive experience in medical device software.

sensiusthermotherapy.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-13
Description

Strategic partnership based on next-generation thermotherapy technology developed at Erasmus MC and commercialized by Sensius. Includes international clinical trial leadership, sponsorship for a PhD, Center of Excellence establishment, and intended sales contract for FocusCollar. Erasmus MC has developed the core technology over two decades with 70+ patients treated. Spin-off from Erasmus MC formalized April 2015.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Pyrexar Medical
TypeDirect peer
Description

Pyrexar Medical (formerly BSD Medical/Perseon Medical) is a US-based manufacturer of microwave and radiofrequency hyperthermia systems for cancer treatment, including systems used in conjunction with radiotherapy for various solid tumors. It is the most direct competitor to Sensius in the microwave hyperthermia device category.

TypeDirect peer
Description

MagForce is a German medical device company that commercializes NanoTherm therapy, a magnetic nanoparticle-based hyperthermia approach for glioblastoma and prostate cancer. It uses a different energy modality (magnetic vs. microwave) but competes in the same oncology hyperthermia space as Sensius.

TypeDirect peer
Description

Oncotherm is a Hungarian-German manufacturer of capacitive hyperthermia devices used as adjuvants to radiotherapy and chemotherapy for solid tumors. It is a direct competitor in the oncology hyperthermia equipment market with established European sales.

TypeDirect peer
Description

Andromedic is an Italian hyperthermia device manufacturer selling capacitive hyperthermia systems in Europe and Southeast Asia. It is both a Sensius channel partner for Italy and a direct competitor in the broader hyperthermia device category.

TypeDirect peer
Description

Celsius42 is a German medical device company developing hyperthermia systems for cancer treatment, with a focus on modular, clinically integrated solutions. It directly competes with Sensius in the European precision thermotherapy space.

TypeEmerging player
Description

Novocure develops Tumor Treating Fields (TTFields), a non-invasive modality for solid tumors including head and neck cancer. It competes with Sensius for oncology budget and radiotherapy workflow integration rather than directly in hyperthermia.

TypeBroad incumbent
Description

Elekta is a global leader in radiation therapy and radiosurgery equipment (linacs, brachytherapy) with which Sensius's thermotherapy workflow must integrate. Sensius's Head of Product Dan Fristedt previously developed linear accelerators at Elekta, and Sensius devices are designed for radiotherapy workflow compatibility.

TypeBroad incumbent
Description

Accuray develops the CyberKnife and TomoTherapy radiation therapy systems used in head and neck cancer treatment. It competes for radiotherapy capital budgets and workflow slots where Sensius thermotherapy would be deployed.

TypeBroad incumbent
Description

Varian (now part of Siemens Healthineers) is the dominant global supplier of linear accelerators and radiotherapy treatment planning software. Sensius's WaveAdapt software and FocusControl are designed to integrate with Varian/Elekta-style radiotherapy workflows, and Varian represents both a partner opportunity and a competitive incumbent.

TypeEmerging player
Description

RefleXion Medical develops biology-guided radiotherapy (BgRT) systems that integrate PET imaging with radiation delivery for solid tumors including head and neck cancer. It represents an emerging alternative modality competing for the same oncology patient population Sensius targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sensius

Oncology Medical Devicessensiusthermotherapy.com

Sensius B.V. is a Dutch medical device company developing the modular Focus thermotherapy platform (FocusCore base unit with body-site applicators) that heats solid tumors to 40-44°C to enhance radiotherapy, chemotherapy, and immunotherapy efficacy, initially targeting head and neck cancer clinics across Europe, the UK, and the USA.

What Sensius does

Sensius B.V. is a Dutch medical device company developing precision thermotherapy systems for solid tumor treatment, founded in 2015 as a spin-off from Erasmus MC Cancer Institute in Rotterdam. The company targets oncology departments at major cancer treatment centers, initially focused on head and neck cancer with planned expansion into breast cancer, melanoma, and sarcoma. Sensius's core value proposition is enhancing the efficacy of radiotherapy, chemotherapy, and immunotherapy by heating tumors to 40-44°C while preserving surrounding healthy tissue, addressing the 50% recurrence rate in head and neck cancer patients and reducing treatment toxicity without adding systemic side effects.

Sensius's platform centers on the FocusCore base unit, which houses 20 independently controlled microwave amplifiers, water cooling systems, and integrated control computers. Body-site specific applicators connect to the FocusCore: the FocusCollar for head and neck cancer (initial commercial product), with pipeline products including FocusCup (breast cancer with chemotherapy), FocusBlanket (melanoma with immunotherapy), and FocusExtremity (sarcoma for arms and legs). The FocusControl software, based on patented WaveAdapt technology, provides adaptive treatment planning customized per patient. Two patents protect the HyperCollar4D technology. Sensius holds ISO 13485:2016 certification (obtained February 2024), with regulatory filings planned for CE Mark in Europe, UKCA marking in early 2026, and IDE filing in the USA. Clinical evidence is being built through 70+ prototype treatments at Erasmus MC, with the TRIHAN trial demonstrating 81.8% complete response in recurrent HNC patients and a 50% improvement over radiotherapy alone.

Sensius operates a B2B enterprise sales model targeting hospitals and cancer centers, with revenue intended to come primarily through capital equipment sales of the Focus system plus body-site applicators. The go-to-market relies on clinical trial partnerships at leading academic centers (Erasmus MC, Charité Berlin, UK clinics, US clinics), followed by regulatory approval and reimbursement-driven adoption. Channel partners support international distribution: AMG Medtech covers the UK and Ireland, while Andromedic represents Sensius in Italy. The Netherlands has reimbursement in place, with roadmaps being developed for Germany, the UK, and the USA. Pre-commercial at present, Sensius is funded by €21.7M+ in equity and grants, with a €15M Series A completed in June 2025 led by GrayBella Capital and UCEA Capital Partners.

Sensius firmographics

Firmographics
Name
Sensius
Legal name
Sensius B.V.
Website
https://sensiusthermotherapy.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Sensius B.V. is a Dutch medical device company developing the modular Focus thermotherapy platform (FocusCore base unit with body-site applicators) that heats solid tumors to 40-44°C to enhance radiotherapy, chemotherapy, and immunotherapy efficacy, initially targeting head and neck cancer clinics across Europe, the UK, and the USA.
Ownership category
akta.pro rank

Sensius industry classification

Industry
Product category
Oncology Medical Devices
NAICS
Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAFAC
Radiation Oncology

Keywords

  • Precision thermotherapy
  • Oncology medical devices
  • Microwave hyperthermia systems
  • Cancer treatment devices
  • Adaptive treatment planning

Where Sensius is headquartered

Location

Headquarters

HQ city
Rotterdam
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Sensius business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales (Focus System): Sensius generates revenue from selling its thermotherapy medical device system (FocusCore + applicators) to hospitals and cancer treatment centers. The system is modular, with a base unit and body-site specific applicators sold as add-ons. Pricing follows a capital equipment model typical for medical devices, with reimbursement enabling hospital procurement.
  2. Clinical Trial Services: Revenue may be generated through clinical trial support and product development collaborations with research institutions, funded via grants and partnership agreements.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Sensius product offering

Product offering

Core offering

Sensius develops a precision thermotherapy medical device system that delivers controlled microwave hyperthermia (40-44°C) to solid tumors in combination with radiotherapy, chemotherapy, or immunotherapy. The modular Focus platform consists of the FocusCore base unit (height-adjustable bed, twenty independently controlled microwave amplifiers, water cooling, control computers) and body-site specific applicators (FocusCollar for head and neck cancer, FocusCup for breast cancer, FocusBlanket for melanoma, FocusExtremity for sarcoma). Treatment is planned and delivered via the FocusControl software based on patented WaveAdapt technology with MR-based temperature measurement.

Product overview

Sensius offers a modular thermotherapy platform consisting of the FocusCore base unit and body-site specific applicators (FocusCollar, FocusCup, FocusBlanket, FocusExtremity) with associated FocusControl treatment planning software. The FocusCore houses twenty independently controlled microwave amplifiers, water pumps, and control systems that power the various applicators. The FocusCollar is the initial commercial launch product for head and neck cancer, while FocusCup (breast cancer), FocusBlanket (melanoma), and FocusExtremity (sarcoma) are in the pipeline for expansion to other solid tumors. The system delivers targeted heating to tumors at 40-44°C in combination with radiotherapy, chemotherapy, or immunotherapy to enhance treatment efficacy.

Differentiator

Problem solved

Functional benefit

Brands

  • FocusCollar: Body-site specific add-on to FocusCore for head and neck cancer treatment with positioning antennas and bolus
  • FocusCup
  • FocusBlanket
  • FocusExtremity
  • FocusCore
  • FocusControl

Products and services

  • FocusCore Base unit comprising a height-adjustable bed, twenty independently controlled microwave amplifiers, water pumps and cooling system, nurse station and control computers. The modular core system that powers all body-site specific applicators and contains all components needed for treatment of all tumor types.
  • FocusCollar Body-site specific add-on to FocusCore for head and neck cancer treatment. Positions antennas around the target area and connects microwave energy to the body via a body-site specific bolus, redesigned with novel technology from Erasmus MC and TU-Delft for improved antenna-to-patient connection and focused energy delivery.
  • FocusControl Software providing accurate treatment preparation and delivery, customized to individual patients. Based on WaveAdapt patented technology, includes automated steering of heat treatment using MR-based temperature measurement across the entire target volume.
  • HyperCollar4D (Focus System) Next-generation thermotherapy device that increases effectiveness of radiotherapy for head and neck cancer by warming tumors to 43°C. The first device to achieve effective and cost-efficient hyperthermia treatments for head and neck cancer, protected by two patents (one granted, one filed).
  • FocusCup Breast cancer applicator in development for use with chemotherapy, expanding the Focus product family to additional solid tumor types by enhancing chemotherapy efficacy through targeted thermotherapy.
  • FocusBlanket Melanoma treatment applicator in development for use with immunotherapy, expanding thermotherapy applications to skin cancer by activating immune response through controlled heating.
  • FocusExtremity Sarcoma treatment applicator for arms and legs in development for use with chemotherapy, extending thermotherapy to extremity tumors.

Quantifiable outcome

  • 50% improvement in complete response rate when thermotherapy added to radiotherapy (vs radiotherapy alone in TRIHAN trial)
  • +5 more outcomes

Companies that use Sensius

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles2 records

Sensius technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Sensius partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core.

  • US Clinical Trial Network (6 clinics)coreStrategic or Co-development Partner · 6 March 20246 US-based clinics participated in Phoenix meeting (ASTRO) to discuss Phase I-III clinical protocols for FDA clearance and reimbursement. Led by Jason Molitoris (UoM Baltimore) with Mark Hurwitz (MC Westchester) presenting mechanism of action.
  • TU/e (Eindhoven University of Technology)coreStrategic or Co-development Partner · 20 November 2023SENS-THERM project partner (electromagnetic sensing, video control, metamodeling in thermotherapy for H&N cancers). Prof. Maarten Paulides leads EM4C&C lab at TU/e. Co-founder Prof. Paulides maintains academic appointment.
  • UK Thermotherapy Special Interest GroupcoreStrategic or Co-development Partner · 20 October 2023Multi-clinic collaboration including Kings College London, Queen Elizabeth Hospital Birmingham, and Clatterbridge Cancer Centre, with NHS radiotherapy ODN and MacMillan Cancer Support representation. Organized by Prof. Bodis and AMG Medtech.
  • AndromediccoreChannel Partner/ Reseller/ Distributor · 3 October 2023Letter of Intent signed at ESHO Cologne for marketing and sales in Italy. Andromedic is an established hyperthermia device manufacturer selling capacitive devices in Europe and SE Asia. Will represent Sensius as sales agent and collaborate on Italian oncology society engagement and clinical trial design for reimbursement.
  • Prof. Stephan Bodis (Medical Advisor)coreOthers · 13 September 2023Prof. Em. Stephan Bodis serves as senior medical advisor. Previously head of department at Kantonspital Aarau, where he established hyperthermia reimbursement in Switzerland and built Swiss Hyperthermia Network of 15 clinics. Brings 20 years of hyperthermia leadership.
  • Inselspital BerncoreStrategic or Co-development Partner · 29 August 2023Letter of Intent for cooperation on thermotherapy introduction for head and neck cancer. University hospital and tertiary specialized center for H&N cancer in Switzerland. Dr. Emanuel Stutz involved.
  • Kantonsspital AaraucoreStrategic or Co-development Partner · 29 August 2023Letter of Intent for cooperation on thermotherapy for head and neck cancer. Driver of Swiss Hyperthermia Network (15 clinics). Prof. Dr. med. Oliver Riesterer chairs radiotherapy. Prof. Stephan Bodis previously built hyperthermia department here.
  • AMG Medtech LimitedcoreChannel Partner/ Reseller/ Distributor · 2 June 2023UK and Ireland commercial partnership. AMG represents Sensius in these territories and aims to build a network of clinics for clinical trials followed by nationwide adoption. Medical imaging consultancy with extensive radiotherapy community network.
  • Charité Universitätsmedizin BerlincoreStrategic or Co-development Partner · 26 April 2023LOI signed for cooperation in product development, consultancy, reimbursement, and clinical trials. Prof. Dr. Daniel Zips (Head of department) leads. Will conduct first-in-patient testing for CE marking, followed by clinical trials and German reimbursement.
  • Technobis High Tech SolutionscoreStrategic or Co-development Partner · 24 October 2022Partnership for development and production of Sensius thermotherapy device, transitioning prototype to commercial medical device. Technobis specializes in medical device development.
  • Motive EngineeringcoreStrategic or Co-development Partner · 24 October 2022Partnership for medical device software development as part of consortium with Technobis and Sensius. Extensive experience in medical device software.
  • Erasmus MC Cancer InstitutecoreStrategic or Co-development Partner · 13 September 2022Strategic partnership based on next-generation thermotherapy technology developed at Erasmus MC and commercialized by Sensius. Includes international clinical trial leadership, sponsorship for a PhD, Center of Excellence establishment, and intended sales contract for FocusCollar. Erasmus MC has developed the core technology over two decades with 70+ patients treated. Spin-off from Erasmus MC formalized April 2015.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Sensius competitors and assessment

Company assessment

Direct peers

  • Pyrexar Medical: Pyrexar Medical (formerly BSD Medical/Perseon Medical) is a US-based manufacturer of microwave and radiofrequency hyperthermia systems for cancer treatment, including systems used in conjunction with radiotherapy for various solid tumors. It is the most direct competitor to Sensius in the microwave hyperthermia device category.
  • MagForce AG: MagForce is a German medical device company that commercializes NanoTherm therapy, a magnetic nanoparticle-based hyperthermia approach for glioblastoma and prostate cancer. It uses a different energy modality (magnetic vs. microwave) but competes in the same oncology hyperthermia space as Sensius.
  • Oncotherm Kft. Oncotherm is a Hungarian-German manufacturer of capacitive hyperthermia devices used as adjuvants to radiotherapy and chemotherapy for solid tumors. It is a direct competitor in the oncology hyperthermia equipment market with established European sales.
  • Andromedic: Andromedic is an Italian hyperthermia device manufacturer selling capacitive hyperthermia systems in Europe and Southeast Asia. It is both a Sensius channel partner for Italy and a direct competitor in the broader hyperthermia device category.
  • Celsius42 GmbH: Celsius42 is a German medical device company developing hyperthermia systems for cancer treatment, with a focus on modular, clinically integrated solutions. It directly competes with Sensius in the European precision thermotherapy space.

Emerging players

  • Novocure Ltd. Novocure develops Tumor Treating Fields (TTFields), a non-invasive modality for solid tumors including head and neck cancer. It competes with Sensius for oncology budget and radiotherapy workflow integration rather than directly in hyperthermia.
  • RefleXion Medical: RefleXion Medical develops biology-guided radiotherapy (BgRT) systems that integrate PET imaging with radiation delivery for solid tumors including head and neck cancer. It represents an emerging alternative modality competing for the same oncology patient population Sensius targets.

Broad incumbents

  • Elekta AB: Elekta is a global leader in radiation therapy and radiosurgery equipment (linacs, brachytherapy) with which Sensius's thermotherapy workflow must integrate. Sensius's Head of Product Dan Fristedt previously developed linear accelerators at Elekta, and Sensius devices are designed for radiotherapy workflow compatibility.
  • Accuray Incorporated: Accuray develops the CyberKnife and TomoTherapy radiation therapy systems used in head and neck cancer treatment. It competes for radiotherapy capital budgets and workflow slots where Sensius thermotherapy would be deployed.
  • Varian Medical Systems (Siemens Healthineers): Varian (now part of Siemens Healthineers) is the dominant global supplier of linear accelerators and radiotherapy treatment planning software. Sensius's WaveAdapt software and FocusControl are designed to integrate with Varian/Elekta-style radiotherapy workflows, and Varian represents both a partner opportunity and a competitive incumbent.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Sensius social profiles

Digital presence

Sensius compliance and trust

Trust signal

Compliance2 records

Sensius financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sensius leadership team

Management profile

Number of profiles

Profiles15 records

Sensius funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sensius M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sensius

What does Sensius do?

Sensius develops a precision thermotherapy medical device system that delivers controlled microwave hyperthermia (40-44°C) to solid tumors in combination with radiotherapy, chemotherapy, or immunotherapy. The modular Focus platform consists of the FocusCore base unit (height-adjustable bed, twenty independently controlled microwave amplifiers, water cooling, control computers) and body-site specific applicators (FocusCollar for head and neck cancer, FocusCup for breast cancer, FocusBlanket for melanoma, FocusExtremity for sarcoma). Treatment is planned and delivered via the FocusControl software based on patented WaveAdapt technology with MR-based temperature measurement.

Is Sensius a public or private company?

Sensius is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sensius founded?

Sensius was founded in 2015. It employs 11 to 50 people.

Where is Sensius based?

Sensius is headquartered in Rotterdam, Netherlands, in the Europe region.

How does Sensius make money?

Two revenue lines are on record. Medical Device Sales (Focus System) is the primary driver. The others are clinical Trial Services.

Who are Sensius's main competitors?

Direct peers on record are Pyrexar Medical, MagForce AG, Oncotherm Kft., Andromedic and Celsius42 GmbH. Emerging players are Novocure Ltd. and RefleXion Medical. Broad incumbents are Elekta AB, Accuray Incorporated and Varian Medical Systems (Siemens Healthineers).

Does Sensius have an API?

No public API is recorded for Sensius.

What industry is Sensius in?

Sensius's product category is Oncology Medical Devices. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals